Remedium Lifecare Limited (BSE: 539561) has launched its ₹49.19 crore Rights Issue, which will open on April 30 and close on May 14, 2025. The move follows the Bombay Stock Exchange’s approval and is aimed at bolstering the company’s transformation into a vertically integrated, research-led global pharmaceutical player.
The capital raise aligns with Remedium’s recent ₹182.7 crore deal with a UK-based pharma company and will be directed towards boosting working capital, scaling R&D and production, digital transformation, and attracting top talent. A significant portion will go into setting up advanced research labs focused on CNS disorders, metabolic diseases, and oncology. The company also aims to improve financial strength through prepayment of liabilities.
Managing Director Adarsh Munjal stated, “This Rights Issue marks a major milestone toward our vision of becoming a globally recognized, innovation-led pharma company. It offers an exciting opportunity for investors at a compelling price point.” In Kolkata, analysts view Remedium Lifecare’s aggressive expansion and global strategy favorably, especially amid a growing appetite for healthcare investments. Local investors are expected to show strong interest, encouraged by the ₹1 per share offer—significantly below the ₹1.79 closing price on April 25. The rights offer is in the ratio of 61 shares for every 50 held, with renunciation allowed from April 30 to May 9.